102 related articles for article (PubMed ID: 31104090)
1. Interim PET-CT-guided therapy in elderly patients with Hodgkin lymphoma-a retrospective national multi-center study.
Bentur OS; Dann EJ; Paran E; Lavie D; Nachmias B; Ron Y; Dally N; Gutwein O; Herishanu Y; Sarid N; Avivi I; Perry C
Ann Hematol; 2019 Jul; 98(7):1665-1674. PubMed ID: 31104090
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience.
Albano D; Mazzoletti A; Zilioli VR; Muzi C; Crucitti L; Tucci A; Pagani C; Re A; Rossetti C; Giubbini R; Bertagna F
Leuk Lymphoma; 2020 Dec; 61(13):3209-3216. PubMed ID: 32705908
[TBL] [Abstract][Full Text] [Related]
3. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
[TBL] [Abstract][Full Text] [Related]
4. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
Santos FM; Marin JFG; Lima MS; Silva-Junior WF; Alves LBO; Moreira FR; Velasques RD; Atanazio MJ; Maia ACA; Buchpiguel CA; Buccheri V; Rocha V
Ann Hematol; 2024 Jan; 103(1):175-183. PubMed ID: 37796339
[TBL] [Abstract][Full Text] [Related]
5. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
6. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
7. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
[TBL] [Abstract][Full Text] [Related]
8. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma.
Rodríguez Taroco MG; Cuña EG; Pages C; Schelotto M; González-Sprinberg GA; Castillo LA; Alonso O
Nucl Med Commun; 2021 Mar; 42(3):306-314. PubMed ID: 33306628
[TBL] [Abstract][Full Text] [Related]
10. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
[TBL] [Abstract][Full Text] [Related]
11. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.
Filippi AR; Botticella A; Bellò M; Botto B; Castiglione A; Gavarotti P; Gottardi D; Parvis G; Bisi G; Levis A; Vitolo U; Ricardi U
Leuk Lymphoma; 2013 Jun; 54(6):1183-7. PubMed ID: 23035692
[TBL] [Abstract][Full Text] [Related]
12. Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
Cottereau AS; El-Galaly TC; Becker S; Broussais F; Petersen LJ; Bonnet C; Prior JO; Tilly H; Hutchings M; Casasnovas O; Meignan M
J Nucl Med; 2018 Apr; 59(4):589-595. PubMed ID: 28864629
[TBL] [Abstract][Full Text] [Related]
13. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
14. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
15. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
16. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
17. PET-adapted therapy for advanced Hodgkin lymphoma - systematic review.
Amitai I; Gurion R; Vidal L; Dann EJ; Raanani P; Gafter-Gvili A
Acta Oncol; 2018 Jun; 57(6):765-772. PubMed ID: 29345517
[TBL] [Abstract][Full Text] [Related]
18. Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria.
Albano D; Bosio G; Re A; Pagani C; Giubbini R; Bertagna F
Leuk Lymphoma; 2019 Feb; 60(2):326-333. PubMed ID: 29966473
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
20. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
